The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of
…
Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth from 2020
…
Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.”
Groups that represent
…
Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in a new
…
Congressional Medicare advisers yesterday formally recommended replacing the formula Medicare uses to distribute extra payments to safety net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.
The 340B program uses the same calculation—the Medicare disproportionate share adjustment percentage—to determine eligibility
…
More than 100 million Americans—almost one-third of the population, and many of them children—lack access to a usual source of primary care due to a shortage of providers in their community, leading to delays in care, poorer health outcomes, and
…
New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B
…
While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on reliably, a
…
A neurosurgeon at a San Francisco 340B hospital who once was a health policy fellow for U.S. Sen. Bill Cassidy (R-La.) and who is doing research for a free-market oriented think tank has written a stinging reply to former U.S.
…
Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New England Journal
…*Sign up for news summaries and alerts from 340B Report